Selvigaltin (GB1211), an orally accessible small molecule galectin-3 inhibitor designed as being a cure for liver fibrosis and cirrhosis, was evaluated to evaluate the result of hepatic impairment on its pharmacokinetics and protection to address regulatory demands. Contributors were being also excluded if they had clinically important abnormalities in electrocardiogram https://1978336-95-691245.blog-ezine.com/39631061/how-much-you-need-to-expect-you-ll-pay-for-a-good-gb1211